NCT03074318View on ClinicalTrials.gov

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

November 15, 2020

Study Completion Date

November 15, 2020

Conditions
Metastatic LeiomyosarcomaMetastatic LiposarcomaUnresectable LeiomyosarcomaUnresectable Liposarcoma
Interventions
DRUG

Avelumab

Given IV

DRUG

Trabectedin

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

EMD Serono

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT03074318 - Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter